• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    10/3/22 1:35:56 PM ET
    $ADMP
    $ANEB
    $ATXI
    $AURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADMP alert in real time by email

    Gainers

    • LogicBio Therapeutics (NASDAQ:LOGC) shares increased by 641.3% to $2.02 during Monday's regular session. The current volume of 10.3 million shares is 5450.9% of LogicBio Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $66.5 million.
    • Myovant Sciences (NYSE:MYOV) shares moved upwards by 38.78% to $24.93. Trading volume for Myovant Sciences's stock is 6.3 million as of 13:30 EST. This is 853.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.3 billion.
    • Avenue Therapeutics (NASDAQ:ATXI) shares rose 31.16% to $13.22. The current volume of 13.8 million shares is 784.6% of Avenue Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $19.5 million.
    • Bionomics (NASDAQ:BNOX) shares increased by 24.37% to $7.79. The company's market cap stands at $58.5 million.
    • Lucira Health (NASDAQ:LHDX) shares moved upwards by 21.38% to $1.29. As of 13:30 EST, Lucira Health's stock is trading at a volume of 98.0K, which is 190.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $51.6 million.
    • Anebulo Pharmaceuticals (NASDAQ:ANEB) stock rose 20.93% to $3.39. The market value of their outstanding shares is at $79.1 million.

    Losers

    • Clene (NASDAQ:CLNN) shares declined by 30.4% to $1.95 during Monday's regular session. Trading volume for this security as of 13:30 EST is 2.7 million, which is 236.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $123.8 million.
    • Belite Bio (NASDAQ:BLTE) shares fell 19.71% to $26.94. As of 13:30 EST, this security is trading at a volume of 70.5K shares, making up 111.7% of its average full-day volume over the last 100 days. The company's market cap stands at $669.9 million.
    • Adamis Pharmaceuticals (NASDAQ:ADMP) shares declined by 16.53% to $0.17. Trading volume for this security as of 13:30 EST is 2.3 million, which is 331.0% of its average full-day volume over the last 100 days. The company's market cap stands at $24.8 million.
    • Aura Biosciences (NASDAQ:AURA) stock decreased by 16.01% to $15.22. As of 13:30 EST, Aura Biosciences's stock is trading at a volume of 92.6K, which is 130.8% of its average full-day volume over the last 100 days. The company's market cap stands at $445.5 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) stock fell 14.38% to $3.93. As of 13:30 EST, Shuttle Pharmaceuticals's stock is trading at a volume of 694.1K, which is 13.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $52.9 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares decreased by 14.08% to $0.09. As of 13:30 EST, Kintara Therapeutics's stock is trading at a volume of 3.9 million, which is 172.6% of its average full-day volume over the last 100 days. The company's market cap stands at $7.4 million. As per the news, the Q4 earnings report came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMP
    $ANEB
    $ATXI
    $AURA

    CompanyDatePrice TargetRatingAnalyst
    Belite Bio Inc
    $BLTE
    1/26/2026$195.00Buy
    BofA Securities
    Belite Bio Inc
    $BLTE
    1/6/2026$191.00Overweight
    Morgan Stanley
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    Aura Biosciences Inc.
    $AURA
    11/26/2025$13.00Outperform
    Evercore ISI
    Belite Bio Inc
    $BLTE
    11/24/2025$154.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    11/20/2025$105.00Neutral
    Mizuho
    Aura Biosciences Inc.
    $AURA
    5/28/2025$22.00Buy
    H.C. Wainwright
    Aura Biosciences Inc.
    $AURA
    7/25/2024$21.00Buy
    H.C. Wainwright
    More analyst ratings

    $ADMP
    $ANEB
    $ATXI
    $AURA
    SEC Filings

    View All

    Amendment: ContextLogic Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K/A - ContextLogic Holdings Inc. (0002064307) (Filer)

    3/5/26 4:47:03 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form S-8 filed by ContextLogic Inc.

    S-8 - ContextLogic Holdings Inc. (0002064307) (Filer)

    3/5/26 4:25:29 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 10-K filed by ContextLogic Inc.

    10-K - ContextLogic Holdings Inc. (0002064307) (Filer)

    3/5/26 4:20:56 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ADMP
    $ANEB
    $ATXI
    $AURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer De Los Pinos Elisabet was granted 166,000 shares, increasing direct ownership by 41% to 575,815 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    3/3/26 4:06:13 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Gibney Anthony S was granted 71,245 shares, increasing direct ownership by 34% to 278,178 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    3/3/26 4:06:39 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Kilroy Conor was granted 62,339 shares, increasing direct ownership by 37% to 229,573 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    3/3/26 4:06:58 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMP
    $ANEB
    $ATXI
    $AURA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

    10/18/21 11:55:40 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

    6/30/21 5:11:48 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $ANEB
    $ATXI
    $AURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bobbili Raja bought $12,311,558 worth of shares (1,758,794 units at $7.00) (SEC Form 4)

    4 - ContextLogic Holdings Inc. (0002064307) (Issuer)

    2/26/26 8:42:27 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    Large owner Abrams Capital Management, L.P. bought $12,311,558 worth of shares (1,758,794 units at $7.00) (SEC Form 4)

    4 - ContextLogic Holdings Inc. (0002064307) (Issuer)

    2/26/26 8:37:36 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Abrams David C bought $12,311,558 worth of shares (1,758,794 units at $7.00) (SEC Form 4)

    4 - ContextLogic Holdings Inc. (0002064307) (Issuer)

    2/26/26 8:36:32 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ADMP
    $ANEB
    $ATXI
    $AURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Belite Bio with a new price target

    BofA Securities initiated coverage of Belite Bio with a rating of Buy and set a new price target of $195.00

    1/26/26 10:01:23 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Belite Bio with a new price target

    Morgan Stanley initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $191.00

    1/6/26 8:54:10 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio upgraded by Mizuho with a new price target

    Mizuho upgraded Belite Bio from Neutral to Outperform and set a new price target of $194.00

    12/2/25 8:17:09 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $ANEB
    $ATXI
    $AURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ContextLogic Holdings Inc. Reports Fourth-Quarter and Fiscal Year 2025 Financial Results

    OAKLAND, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the fourth quarter and fiscal year ended December 31, 2025. Company Update Subsequent to the end of the fourth quarter 2025, the Company completed the acquisition of US Salt Parent Holdings, LLC and its subsidiaries (together, "US Salt"), marking a pivotal milestone in ContextLogic's evolution into a business ownership platform. The Company remains focused on identifying and pursuing additional acquisitions of businesses that are niche, competitively advantaged, and built for long-duration value creation. Four

    3/5/26 4:10:00 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    Belite Bio to Participate in the Leerink Global Healthcare Conference

    SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc  (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 1:00 pm ET. Webcast Link InstructionsA webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days followin

    3/2/26 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in Q2 2026Completed enrollment in the Phase 2/3 DRAGON II trial in STGD1Completed a $402 million underwritten public offering of American Depositary SharesConference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ET SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerativ

    3/2/26 6:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $ANEB
    $ATXI
    $AURA
    Financials

    Live finance-specific insights

    View All

    ContextLogic Holdings Inc. Reports Fourth-Quarter and Fiscal Year 2025 Financial Results

    OAKLAND, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the fourth quarter and fiscal year ended December 31, 2025. Company Update Subsequent to the end of the fourth quarter 2025, the Company completed the acquisition of US Salt Parent Holdings, LLC and its subsidiaries (together, "US Salt"), marking a pivotal milestone in ContextLogic's evolution into a business ownership platform. The Company remains focused on identifying and pursuing additional acquisitions of businesses that are niche, competitively advantaged, and built for long-duration value creation. Four

    3/5/26 4:10:00 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    ContextLogic to Acquire US Salt from Emerald Lake in $907.5 Million Transaction, Creating New Business Ownership Platform in Partnership with Abrams Capital and BC Partners Credit

    Marks the first step in building ContextLogic into a differentiated business ownership platform. ContextLogic will be focused on owning niche, competitively-advantaged, long-duration businesses run by world-class management teams.US Salt, the first such acquisition, is a 132-year old business producing high-purity evaporated salt products for recession-resilient end markets. Led by a management team with 25+ year record of value creation, US Salt has consistently delivered strong revenue growth, robust margins, and high cash flow generation. ContextLogic shareholders will have the opportunity to commit additional capital in the transaction via a rights offering, which has been fully backstop

    12/8/25 7:30:17 AM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

    FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinic

    12/3/25 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $ANEB
    $ATXI
    $AURA
    Leadership Updates

    Live Leadership Updates

    View All

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Rishi Bajaj, Founder and CIO of Altai Capital Management and CEO of ContextLogic Inc., Joins Digimarc's Board of Directors

    Bajaj brings broad financial and strategic experience to Digimarc Board as the company builds the trust layer for the modern world. Digimarc Corporation (NASDAQ:DMRC), a pioneer in digital watermarking technologies, today announced the appointment of Rishi Bajaj, founder and CIO of private investment firm Altai Capital Management, L.P. ("Altai") and CEO of ContextLogic Inc., to its Board of Directors. Bajaj's qualifications to serve on the board include extensive investment management, operational, and board experience, particularly in the technology sector. Alongside Bajaj's appointment, Digimarc has entered into a cooperation agreement with Bajaj and Altai Capital Management, L.P.. Th

    7/29/25 8:00:00 AM ET
    $DMRC
    $LOGC
    $MOBL
    EDP Services
    Technology
    Catalog/Specialty Distribution
    Consumer Discretionary

    ContextLogic Appoints Finance Executive Michael Scarola as New Chief Financial Officer

    OAKLAND, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (OTC:LOGC) ("ContextLogic," the "Company," "we" or "our") today announced the appointment of Michael Scarola as Chief Financial Officer, effective June 30, 2025. "We are thrilled to appoint Michael Scarola to the position of Chief Financial Officer. This appointment reflects our strategy to streamline our business as much as possible while we pursue value maximation through organic growth and accretive acquisitions." said Rishi Bajaj, Chief Executive Officer. Mr. Scarola currently serves as the Chief Financial Officer, Chief Operating Officer, and Chief Compliance Officer of Altai Capital, and has developed a wide a

    6/25/25 4:30:00 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ADMP
    $ANEB
    $ATXI
    $AURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 5:50:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 4:18:22 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care